News
Ethics Update - Concerns about recent FAMHP guidelines
EPHMRA – concerns about recent FAMHP guidelines
We are aware of significant concerns that healthcare market research studies may not qualify under Belgium’s FAMHP new guidelines on the application of Article 10. The wording in the guidance and subsequent Q&A document appear to overlook key distinctions between bona fide market research vs. promotional / sales-related activities.
EPHMRA Online Webinar: MR Excellence Awards 2024 Future Leaders Award, sponsored by Beyond Blue Insight
06 June – 14.30 UK Time
Convenor: Jenny Fletcher, Beyond Blue
As we look forward to welcoming our delegates to the 2024 EPHMRA Conference, we would like to take the chance to thank our Conference exhibitors.
Here are the members who have taken the opportunity to exhibit:
Visit them during Tuesday, Wednesday and Thursday…
- elma research
- Fine Research
- groupH
- Instar
- KeyQuest Health
Want to find out how market research effects health equity in the real world?
And onto one of Wednesday's 2024 EPHMRA Conference papers…
A huge thankyou to our Conference programme committee!
Without you, the Conference would simply not be possible.
Our Conference Committee are:
Amr Khalil, Ripple International
Erik Holzinger, groupH
Georgina Cooper, Basis Health
Letizia Leprini, Roche
Sarah Phillips, IQVIA
Stephen Potts, Purdie Pascoe
Tracy Machado, Elma Research
‘Utilising in the moment Clickscape data for symptom tracking; a Fibromyalgia patient case study’ presented by Richard Heath, Blue Yonder Research.
Paul Reed, Research Partnership will be presenting his paper: ‘The rise of the healthcare influencer: How influencer culture can support your omnichannel strategy’
The main objective of the paper will be to highlight the role that key online influencers play in both the emotional and pharmacological journey of patients both before and after diagnosis of a condition.
A big thank you to our 2024 conference sponsors!
EPHMRA have had fantastic support in being able to gain sponsorship for the following items:
‘High-Power Patient Involvement: Using Choice Modelling to Inform Forecasting / Uptake’
In this session we will share how methods and tools used in later stage NIS (noninterventional studies) can also be light-weight tools earlier in the product lifecycle and provide quantitative patient/caregiver input with robust analysis - without the burden of a full NIS.